











































Validating differential volatilome profiles in Parkinson’s disease
Citation for published version:
Sinclair, E, Walton-Doyle, C, Sarkar, D, Hollywood, KA, Milne, J, Lim, SH, Kunath, T, Rijs, AM, De Bie,
RMA, Silverdale, M, Trivedi, DK & Barran, P 2021, 'Validating differential volatilome profiles in Parkinson’s
disease', ACS Central Science, vol. 7, no. 2, pp. 300-306. https://doi.org/10.1021/acscentsci.0c01028
Digital Object Identifier (DOI):
10.1021/acscentsci.0c01028
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 17. Aug. 2021
Validating Differential Volatilome Profiles in Parkinson’s Disease
Eleanor Sinclair, Caitlin Walton-Doyle, Depanjan Sarkar, Katherine A. Hollywood, Joy Milne,
Sze Hway Lim, Tilo Kunath, Anouk M. Rijs, Rob M. A. de Bie, Monty Silverdale, Drupad K. Trivedi,
and Perdita Barran*
Cite This: ACS Cent. Sci. 2021, 7, 300−306 Read Online
ACCESS Metrics & More Article Recommendations *sı Supporting Information
ABSTRACT: Parkinson’s disease (PD) is a progressive neuro-
degenerative disorder that does not currently have a robust clinical
diagnostic test. Nonmotor symptoms such as skin disorders have
long since been associated with the disease, and more recently a
characteristic odor emanating from the skin of people with
Parkinson’s has been identified. Here, dynamic head space (DHS)
thermal desorption (TD) gas chromatography−mass spectrometry
(GC-MS) is implemented to directly measure the volatile
components of sebum on swabs sampled from people with
Parkinson’sboth drug naiv̈e and those on PD medications (n =
100) and control subjects (n = 29). Supervised multivariate
analyses of data showed 84.4% correct classification of PD cases using all detected volatile compounds. Variable importance in
projection (VIP) scores were generated from these data, which revealed eight features with VIP > 1 and p < 0.05 which all presented
a downregulation within the control cohorts. Purified standards based on previously annotated analytes of interest eicosane and
octadecanal did not match to patient sample data, although multiple metabolite features are annotated with these compounds all
with high spectral matches indicating the presence of a series of similar structured species. DHS-TD-GC-MS analysis of a range of
lipid standards has revealed the presence of common hydrocarbon species rather than differentiated intact compounds which are
hypothesized to be breakdown products of lipids. This replication study validates that a differential volatile profile between control
and PD cohorts can be measured using an analytical method that measures volatile compounds directly from skin swabs.
■ INTRODUCTION
The use of scent as an indicator for physical (and mental)
biological functions has been associated with many disease
states, such as diabetes mellitus, tuberculosis, liver and kidney
disease, and cancer.1 Although odor can be linked to many
diseases, it is not a commonly applied approach to define
biomarkers in clinical diagnostic tests. The application of canine
detection within the medical field has progressed since a
pioneering report of melanoma detection by Williams and
Pembroke in 1989.2−4 Some characteristic odors released in
bodily secretions and excretions can occur before many other
symptoms of the disease have developed as previously reported
in Parkinson’s disease (PD).5,6
Odorous skin secretions are most frequently related to areas
of high sweat excretion and its subsequent bacterial degradation.
However, sebaceous gland excretion is an alternative process
that produces a biological matrix with a signature due to volatile
organic compound(s) (VOC(s)).7 The production of sebum
from these glands occurs everywhere on the body, with the
exception of the palms of hands and soles of feet, and is most
evident on the face and upper trunk of the body which are
categorized as sebum-rich locations.8
A noteworthy nonmotor symptom of PD is the development
of skin-related disorders such as seborrheic dermatitis (SD),
which occurs in up to 60% of PD patients and manifests as an
increase in sebum production.9,10 The analysis of volatile species
from skin secretions such as sebum and sweat is an under-
developed methodology for clinical applications, and hence,
there is no recognized standard procedure for its sampling.11,12
Gauze swabs,13 polydimethylsiloxane (PDMS) patches,14
cigarette papers,15 glass rollers or beads,16,17 and more advanced
methods such as wearable iontophoresis biosensors18 have been
previously reported, all of which have associated advantages and
disadvantages in application.19 These methods have primarily
been directed to the collection of sweat rather than sebum, the
waxy lipid-rich component.
The chemicals associated with these odorous profiles belong
to the VOC class. There has been a rise in the development of
analytical techniques to measure VOCs for clinical applications,
most notably in the advancement of “electronic noses” and
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within the field of breathomics.20−24 Analysis of VOCs using gas
chromatography−mass spectrometry (GC-MS) is a popular
nonselective analytical technique in which complex mixtures are
separated prior to m/z detection of molecular ions and
corresponding fragment ions to aid in structural elucidation.
Headspace analysis, either dynamic or static, is a technique
which promotes the volatile components of a sample to enter the
gaseous “headspace” of an enclosed vessel by the partition of a
concentration gradient, often using a temperature incubation
prior to sampling to enhance the process.25,26 While both
techniques are effective, dynamic headspace (DHS) analysis has
the benefit of concentrating volatile species through the
continuous collection of the headspace which is an obvious
benefit for untargeted metabolomics.25
This study leads on from earlier work which demonstrated
that there was a differential VOC signature in Parkinson’s
disease patients.5 This subsequent study provides a completely
independent validation set of data using a different instrument
alongside new patient samples.
■ EXPERIMENTAL METHODS
Sample Participants. The participants included within this
study were part of a nationwide recruitment process taking place
at 25 different NHS clinics across the UK. This study consists of
a subset of 129 participants from three subject groups:
independent controls (n = 29), drug naiv̈e Parkinson’s disease
participants (n = 17), and medicated Parkinson’s disease
participants (n = 83). Patient demographics are reported in
Table S1. Ethical approval for this project (IRAS project ID
191917) was obtained by the NHS Research Authority (REC
references: 15/SW/0354).
Sample Collection. Each participant was swabbed on the
upper back with cotton-based sterile medical gauze (7.5 cm ×
7.5 cm) to collect sebum present on the skin. Participants were
asked not to wash 24 h before sebum collection. We have not
controlled for diet or water intake, but we expect this variation to
be more random in subjects than the effect of disease. The
patient sampled gauze was sealed in background-inert plastic
bags and transported to the central facility at the University of
Manchester, where they were stored at −80 °C until analysis.
Chemicals and Materials. The chemicals and materials
used in this study were gauze swabs (Arco, UK), sterile sample
bags (GE Healthcare Whatman, UK), 20 mL glass vials
(GERSTEL, Germany), TENAX TA thermal desorption tubes
and liners packed with TENAX TA for CIS 4/6 liner for the
thermal desorption unit (TDU) (GERSTEL, Germany),
Optima LC-MS grade methanol (Fisher Scientific), and
HiPerSolv CHROMANORM absolute ethanol 99.8% purity
(VWR Chemicals). The QC sample was composed of a mixture
of seven compounds, each sourced from Sigma-Aldrich; L(−)-
carvone (27.0 μM), δ-decalactone (96.4 μM), ethyl butyrate
(150.5 μM), ethyl hexanoate (30.5 μM), hexadecane (43.7 μM),
nonane (83.07 μM), and vanillin (100.8 μM), all in
MeOH:EtOH (9:1). Octadecanal (Apollo Scientific) and
eicosane (Sigma-Aldrich) standards were both 99% purity.
DHS-TD-GC-MS Analytical Method. Thawed gauze swabs
were aseptically transferred into 20 mL glass vials and analyzed
by DHS-TD-GC-MS (TD, thermal desorption). During DHS
preconcentration, the samples were incubated at 80 °C for 10
min to promote the concentration of VOCs in the vial
headspace. Trapping was initiated with dry nitrogen as the
purge gas at a flow rate of 70mLmin−1 for a total gas volume of 1
L. The volatile compounds were captured on a TENAX TA
adsorbent tube (GERSTEL, Germany) held at 40 °C. The
adsorbent tube was transferred from the DHS unit to the TD
unit (TDU) using an automated GERSTEL MPS dual head
workstation, at which time the captured VOCs were desorbed
from the TENAX sorbent. The TDU was operated in splitless
mode and was held at 30 °C for 1 min before the application of a
12 °C s−1 temperature ramp and held at 280 °C for 5 min. The
desorbed analytes were focused in a cooled injection system
(CIS) which was operated in solvent vent mode, using a vent
flow of 80mLmin−1. The CIS was held at 10 °C for 2min before
a second 12 °C s−1 temperature ramp and maintained at 280 °C
for 5 min. The CIS vent valve (and flow) was not initiated until 3
min after analyte release on the GC column and can therefore be
classed as a splitless method. The GC analysis was performed on
an Agilent GC 7890A coupled to an Agilent MSD 5975 system
interfaced by an electron impact (EI) source. Separation was
induced by an Agilent VF-5MS column (30m× 0.25mm× 0.25
μm). The column flow was kept at 1 mL min−1. The oven ramp
was programmed as follows: 40 °C held for 1 min, 25 °C min−1
to 180 °C, 8 °C min−1 to 240 °C and held for 1 min, and 20 °C
min−1 to 300 °C held for 2.9 min for a total run time of 21 min.
The transfer line to the MS was maintained at 300 °C, the EI
source at 230 °C, and the Quadrupole at 150 °C. The mass-
selective detector (MSD) was operated in scan mode for a mass
range between 30 and 800 m/z. The GC-MS system is fitted
with a GERSTEL olfactory detection port (ODP3) using
Agilent Technologies capillary flow technology (three-way
splitter plate equipped with makeup gas). This was controlled
as a 1:1 (v:v) split between MSD and ODP, and therefore, the
GC eluent was diluted by a factor of 2 with helium makeup gas.
Patient SampleAnalysis.Gauze samples from 129 subjects
were analyzed across seven stratified, randomized, and blinded
analytical batches. Quality control (QC) samples were injected
at the beginning (n = 3), after every fifth injection, and at the end
(n = 3) of each batch analysis. QC samples (5 μL) were used to
gauge the analytical reproducibility in batch-to-batch analyses,
which were analyzed on a shorter DHS-TD-GC-MS method to
enable a faster analysis time per analysis batch. An example
chromatogram for a PD sample and a control sample is shown in
Figure S1A,B, respectively.
Analyte of Interest Standards Analysis.Octadecanal and
eicosane standards were run on an identical DHS-TD-GC-MS
method to patient samples. Headspace sampling was performed
with 10 μL of octadecanal (37.4 μM) and eicosane (35.4 μM) in
MeOH which were individually analyzed in 20 mL vials.
Lipid Standards Analysis. Lipid standards were purchased
from Avanti Polar Lipids [L-α-phosphatidylethanolamine
(Brain, Porcine) (PE), L-α-phosphatidylserine (brain, porcine)
(sodium salt) (PS), and 1′,3′-bis[1,2-dioleoyl-sn-glycero-3-
phospho]-glycerol (sodium salt) (18:1 cardiolipin) (CL)] and
were diluted in CHCl3 while L-α-phosphatidylcholine (brain,
porcine) (PC) was diluted in MeOH. Glucosylsphingosine
(GlcSph) (Sigma-Aldrich) was diluted in MeOH. All standards
were analyzed using a slightly varied analytical method to that of
the patient samples; the changes were as follows: a 5 min solvent
vent was applied in addition to a further 4 min high-temperature
hold at the end of the GC temperature gradient. The analytical
method was 25min in total. From a standard solution of 100 μM
total, a 20 μL portion was analyzed in separate headspace vials.
Lipid standards were measured in triplicate alongside blank
headspace vials and blank solvent analyses (both MeOH and
CHCl3) which were measured both prior to and after lipid
standard analysis. A comparative example of a lipid standard (L-
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α-phosphatidylethanolamine (Brain, Porcine) (PE)), blank
headspace vial, and solvent-only analysis is reported as overlaid
chromatograms in Figure S1C.
Data Preprocessing and Deconvolution. All TD-GC-
MS patient sample and lipid standard data were converted to
open source mzML format using ProteoWizard.27 The data set
was deconvolved using an in-house script using the eRah
package for R.28 The deconvolved analytes were assigned
putative identifications by matching fragment spectra with
compound spectra using the Golm database. The resulting
matrices comprised variables and their corresponding peak areas
per sample. The patient sample data set comprised 671 features,
and these were further refined by the removal of features absent
in more that 5% of all samples, which generated a reduced data
set of 520 features.
Features present in lipid standard data were filtered based
upon a set of further criteria: (a) match factor (MF) > 75, (b)
detection only in lipid sample analysis and not present in either
the blank headspace vial or solvent-only analyses, (c) abundance
> 1000 counts, and (d) each feature present in at least two of
three triplicate analyses.
Statistical Analysis.We used a two-pronged approach with
the statistical investigation of data. A data-driven multivariate
approach was used to validate if there was a differential VOC
signature associated with PD. Further, a targeted approach was
used to verify selective analyte of interest peaks. Data were
autoscaled and all missing values replaced using spline
interpolation prior to statistical analysis. To account for
variances in sebum production between participants, all samples
were normalized to their respective TIC. There was less than an
order of magnitude difference between samples which had the
highest and lowest summed total ion count (TIC) (1.23 × 108
and 2.73 × 107). Of the five samples with the highest summed
TIC, one was the control, and four were PD; of the five samples
with the lowest summedTIC, one was the control, and four were
PD. To further investigate that effect of biomass variations, we
considered the relative intensities of common ions in high- and
low-response samples in both cohorts. The four highest and four
lowest summed TIC samples for both PD and the control were
chosen, totalling 16 reference samples. Features not present in
all of these 16 samples were removed, and all features were
normalized to their respective TIC. There were no trends in the
features as a proportion of summed TIC, demonstrating that the
amount of sebum sampled does not necessarily correlate to the
composition. Examples of plots of normalized intensities in four
representative features are reported in Figure S2A−D.
The synthetic minority oversampling technique (SMOTE)
was implemented to balance the sample numbers within each
class and hence remove possible bias to the majority class.29
Partial least-squares-discriminant analysis (PLS-DA) was
executed in MATLAB (2019a) for classification and prediction
of classes within data.30,31 Models were validated by resampling
bootstrapping (n = 250). Multivariate receiver operating
characteristic (ROC) analysis was performed using Metab-
oAnalyst Biomarker Analysis (Version 4.0);32 PLS-DA was
implemented for classification and feature ranking with a two
latent variable input. PLS-DA score plots for PD vs control and
drug naiv̈e PD vs medicated PD classification models are
reported for reference in Figure S3A,B, respectively. ROC curves
were generated by balanced Monte Carlo cross validations
(MCCVs) in which two-thirds of the samples were used to
evaluate feature performance, and the remaining one-third were
used to validate the classification. Iterations of this process (n =
30) were performed to calculate model performance and
calculate confidence intervals for area under the curve (AUC)
for each model.33 Like any metabolomics data, sebum produces
a highly complex set of features. This is mostly due to high-
resolution mass spectrometry and very sensitive detectors.
Principal component analyses (PCAs) are often successful for
classification purposes when the data come from a really clean
system such as microbiome data where metabolism is well-
defined, and perturbation responses are very unique, i.e., KO vs
WT or growth condition differences. With human biological
samples, complexity is very high, and often PCA orMDS are not
the best approaches to classify data due to subject-to-subject
variations.5 At best, PCA is a good tool for dimensionality
reduction in such cases.
PLS-DA models without appropriate validations certainly can
be prone to overfitting or just picking up on noise. This study
was blinded, performed in batches, and randomized, so if any
analytical artifact was introduced, it would not affect only one
class in our supervised approach. Any random effect wouldmake
the model worse than what we have shown. We believe this is
encouraging because without highly controlled data set, the
volatilome between PD and the control is so different that we
have high classification accuracy by modeling this data. With
future work where we can have better libraries to annotate
metabolites of interest, control for diet, and/or exposome under
our new ethics, lesser noise will further improve supervised
models.
■ RESULTS AND DISCUSSION
Validating Changes within VOC Profiles with the
Onset of PD. To assess and validate if there are measurable
discriminant VOCs in sebum, PLS-DA models were generated
from new independent data. Models were generated to analyze
(i) the classification accuracy between PD (drug naiv̈e and
medicated) and control samples and (ii) drug naiv̈e PD against
medicated PD participants to investigate differences in the
disease phenotype alongside any possible effects of medication
on this measured phenotype. An average correct classification
rate (CCR) of 84.4% was obtained by combining the drug naiv̈e
and medicated PD cohorts in which the CCR was validated via
bootstrapping (n = 250) (Figure 1). This prediction rate is
similar to the average CCR (86%) achieved by PLS-DA with 5-
fold cross validation reported in our pilot study.5 Patient
demographics were assessed to determine if they impacted the
classification accuracy within the model. This is discussed in
detail within the Supporting Information alongside significance
tests for metadata parameters (Table S2). In summary, no
significant confounding effects were observed on PLS-DA
classification due to gender (Figure S4), BMI, alcohol intake or
smoking (Figure S5), or age.
This classification validates findings from our initial TD-GC-
MS study which revealed a unique VOC signature that can be
associated with PD patients and be measured by the headspace
sampling of sebum collected noninvasively. It is noted that the
measured VOC profiles between drug naiv̈e PD and medicated
PD cohorts did not classify well, with a CCR of 66.7%, and had
poor validation by permutation testing (Figure 2). This indicates
that the sampled VOCs do not have sufficient discriminatory
power to classify between drug naiv̈e and medicated PD but can
distinguish PD from the control, indicating that the associated
odor profile is fundamental to PD. It can therefore be
hypothesized that there is minimal change within the VOC
profile after the onset of PD, with treatment, and/or that our
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classification of the disease based on drug naiv̈e vs medication
does not translate well to clinical PD staging.
Discriminatory Features in PLS-DA Classification
Modeling. Variable importance in projection (VIP) scores
were calculated for the two-class PLS-DA model: combined PD
vs controls. A multivariate ROC analysis was performed for
compounds (n = 12) with VIP score >1 (Figure 3A). The area
under the curve (AUC) values increase as the number of features
included in the model increases, in conjunction with a reduction
in the confidence interval (CI) range. The predictive power of
the model increases going from a two-variable classifier up to
seven-variable classifier; however, it begins to plateau following
this threshold. The compounds that had high VIP scores (top
10%) were further selected (n = 50), and ROC analysis was
performed, showing the same trend of increasing AUC values
until a plateau between the 5-variable and 10-variable models,
which is consistent with the previous ROC analysis (VIP > 1).
This is presented in Figure S6.
Mann−Whitney nonparametric U tests between PD and
control cohorts were performed for selected compounds (VIP >
1), and eight of these compounds were found to be statistically
significant with p < 0.05 (reported in Table S3). ROC analysis of
these compounds provides an improved classification model
(Figure 3B) in which the addition of all eight features improves
the AUC to 0.872 and the lowest CI range (0.801−0.942).
Figure S7 displays the individual ROC curve for each added
compound in this model. Due to limitations of volatile
compound identification within this study, species are simply
referred to as “VIP features” (1−8). Box and whiskers plots for
these eight compounds are reported in Figure S8 alongside
calculated fold changes (nonscaled). Each feature is down-
regulated within the PD cohort with fold changes ranging from
0.2 to 0.73 between PD and control cohorts.
Targeted Analysis of Previously Identified Analytes of
Interest. The following stage of the study concerned
investigating the presence and significance of a panel of analytes
of interest obtained from the results of our previous study.34 A
targeted data analysis approach was performed for the four
target compounds: octadecanal, eicosane, hippuric acid, and
perillaldehyde. The data matrix revealed that multiple features
were annotated with the same compound identification for each
Figure 1. PLS-DA classification model for a two-class input using
combined drug naiv̈e and medicated PD cohorts vs controls. (A)
Histogram reporting the distribution of the correct classification rate for
the null (gray) and observed (blue) distributions obtained from
bootstrap validation (n = 250) of the PLS-DA classification model. (B)
Chart displaying the true positive (TP), true negative (TN), false
positive (FP), and false negative (FN) classification rates.
Figure 2. PLS-DA classification of drug naiv̈e PD vs medicated PD in
which medicated PD was the positive predictive class. (A) Histogram
reporting the distribution of correct classification rates (CCRs) for the
null (gray) and observed (blue) distributions obtained from bootstrap
validation (n = 250) of the PLS-DA classification model. (B) Chart
reporting the classification rates from the PLS-DA model.
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of these targets based upon high similarities of their
fragmentation pattern signatures. Database spectral matching
typically returns a match factor (MF), in this case between 1 and
100, which indicates the similarity of an experimentally recorded
spectrum to that of a database spectrum based on the presence of
molecular and fragment ion peaks and their relative intensities.
Eicosane and octadecanal each returned three identification
matches, separately, in which these annotations were the
primary ID, falling within a 2−3 min retention time (RT)
window. Standards of eicosane and octadecanal were analyzed
using an identical analytical method, and the corresponding
reference spectra were matched against these highlighted
features within the patient sample sebum data. Although
retention times could not be matched, there was a high
similarity between mass spectra (MF > 90). It can be inferred
that these putative assignments based on spectra matching result
from closely related molecular species that have large hydro-
carbon chains, for example, lipids. Sebum is composed of a large
number of lipid species such as triglycerides, fatty acids, and wax
esters.35,36 Thus, it is not surprising to observe multiple closely
related lipid peaks.
To corroborate this inference, lipid standards were purchased
and analyzed to investigate the resultant chromatographic
spectra from known standards. Evidence from two parallel
studies analyzing PD and control sebum, using liquid
chromatography-MS37 and paper spray-MS,38 have shown that
the primary compounds of interest can be putatively assigned to
a series of lipids. Lipid mixtures were investigated to distinguish
the type of species detected in (nonderivatized) lipid DHS-TD-
GC-MS experiments and to then evaluate their compound
annotation in the same libraries. Each lipid standard mixture
yielded a large number of resolvable compound features across
each chromatogram that had high database spectral MF scores
and good reproducibility across replicates. Between 68% and
87% of these features were annotated as hydrocarbon species
assigned to at least two detected variables. A list of the
hydrocarbon species detected within the lipids standards data is
reported in Table 1, alongside the number of discrete features
provided with this annotation. Definitive annotation of large,
chemically similar hydrocarbons, like lipids, is challenging
because of the obvious similarities expected in their fragment
products. This is further confounded by the large number of
conceivable structural isomers for each hydrocarbon; for
example, dodecane, the most frequently detected species in
the data, has 355 possible isomers. These experiments were
repeated using a traditional liquid injection GC-MS exper-
imental setup for the analysis of some of these lipid standards
(Table S4), and a similar trend in recurring hydrocarbon
features was noted. We hypothesize that the overlap of
compound annotations across distinct deconvolved features in
our patient sample sebum data arises from the decomposition of
lipid species.
For example, lipid oxidation is a well-known mechanism for
lipid degradation and can proceed via an assortment of pathways
dependent on the lipid and enzyme in question and the type of
oxidation. These reactions produce a variety of product species
including hydrocarbons, alongside aldehydes, ketones, alcohols,
esters, and acids.39,40 Therefore, the multiple instances of
hydrocarbon species that are reproducibly detected throughout
lipid-based chromatographic analyses (both patient sample and
from standards) are due to lipid decomposition. Such
degradation can lead to an accumulation of large concentrations
of common hydrocarbon chains of different lengths. Similar
products due to the loss of more distinctive structural moieties,
such a lipid head groups, are readily observed upon collisional
Figure 3.Multivariate ROC curve analyses to evaluate the performance
of VIP compounds in biomarker models. Resampling was used to
calculate 95% confidence intervals (CIs) using a Monte Carlo cross
validation (MCCV) approach. (A) Each colored line represents the
ROC curve using a specific number of variables; these are listed in the
bottom right-hand corner from red (2-variable) to yellow (12-variable),
generated from all compounds with VIP > 1. (B) ROC curve displaying
the sensitivity and specificity of all eight-variables (VIP > 1, p < 0.05)
combined; the shaded bands represent the 95% CI for this model.
Table 1. Putative ID and Chemical Formula of the
Hydrocarbon Species Present within the Lipid Standards
Dataa
number of features
putative ID chemical formula PE PC PS CL GlcSph
decane C10H22 2 0 2 2 0
dodecane C12H26 9 4 6 7 6
tridecane C13H28 1 0 0 1 0
tetradecane C14H30 2 0 2 0 0
pentadecane C15H32 2 0 2 2 2
hexadecane C16H34 6 1 2 6 1
heptadecane C17H36 2 2 4 3 1
nonadecane C19H40 0 0 1 2 0
eicosane C20H42 2 2 4 3 0
heneicosane C21H44 0 0 0 0 1
docosane C22H46 0 1 0 1 0
tricosane C23H48 3 0 3 2 0
tetracosane C24H50 0 0 0 0 2
aThe number of distinct features that are annotated with each given
compound ID is listed beside. The lipid abbreviations are as follows:
PE, phosphatidylethanolamine; PC, phosphatidylcholine; PS, phos-
phatidylserine; CL, cardiolipin (18:1); and GlcSph, glucosylsphingo-
sine.
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activation and in source dissociation of these labile compounds.
These results provide a vital insight into the expected profile
upon analysis of the hydrocarbon-rich lipid-based biological
matrix that is sebum. The identification of pure, large-molecular-
weight lipid standards by GC-MS is challenging, and data shown
here yield an array of product species across the chromato-
graphic domain; unquestionably, the myriad of endogenous and
exogenous compounds in sebum will offer a greater challenge.
Prior to the generation of comprehensive annotated databases
that reflect this chemical complexity, it is likely that biomarker
detection will consist of Metabolomics Standards Initiative
(MSI) level 2 feature detection rather than the verification of
compounds.
The remaining two analytes of interesthippuric acid and
perillaldehydewere only annotated as a derivatized form with
trimethylsilyl and methoxime adducts, respectively. Again,
multiple features were assigned these annotations, and they
spanned a wide chromatographic time range; therefore,
annotation of neither of these analytes of interest could be
reliably verified within this data set. A direct limitation of
analyzing a biological matrix without derivatization is the limited
compound annotation using commercial databases, which are
composed majorly of derivatized compounds. The dominating
method in GC-MS analysis for metabolomics approaches uses
chemically derivatized sample extracts, and therefore, bio-
logically relevant compound spectra are often of derivatized
forms. Further work is needed in the area of database curation
for nonderivatized, biologically relevant, volatile species present
in a sebum as a biological matrix, to enable confident compound
identification using DHS-GC-TD-MS.
■ CONCLUSION
Volatile organic compounds from sebum measured using DHS-
TD-GC-MS can accurately discriminate between PD and
control samples. Our results validate previous findings that
VOCs measured from skin have a differential profile in
Parkinson’s disease that can be modeled using PLS-DA analysis.
Putatively annotated analytes of interest from our previous study
could not be validated within this data set. However, multiple
features were putatively annotated as two of these candidates
(octadecanal and eicosane), and derivatized compound
annotations were associated to the remaining two analytes of
interest (hippuric acid and perillaldehyde). Spectral matching to
an in-house database of standards, viz. octadecanal and eicosane,
yielded high spectral similarity (MF > 90), although retention
times did not match. This leads us to conclude that these
compounds have very similar structures and/or could be
common breakdown products of larger species in which the
discriminatory structural moiety was lost as a neutral fragment.
This hypothesis was strengthened with the analysis of lipid
standard mixtures, which reveal the detection of common
hydrocarbon species. Compounds selected using VIP score-
based ranking from PLS-DA modeling performed well in
multivariate ROC analysis, and each metabolite feature showed
a fold change relating to a lower expression in PD samples.
These compounds have not been annotated with putative
identifications due to poor performance of database matching to
available GC-MS mass spectra libraries. Future studies will
create an in-house GC-MS database for both spectral and RT
matching that will address the current bottleneck in the field for
annotation of nonderivatized, biologically relevant VOCs.
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